Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more ...
4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...
MyChesCo on MSN15h
FDA Greenlights Ocugen’s Breakthrough Gene Therapy Trial, Offering New Hope for Stargardt Disease Patients
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced a significant milestone with the U.S. Food and Drug Administration (FDA), ...
Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs
Goldman Sachs analyst Richard Law lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $15 from $29 and keeps a Neutral rating ...
Santé log20h
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
In the United States, ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is investigational.
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and ...
Patriots head coach Mike Vrabel jabs Travis Hunter, tells prospect he's 'not the only one to play two ways'
T he most unique prospect in recent memory to come through the NFL Draft is Colorado's Travis Hunter. Why? Well, he just ...
Rocket Pharmaceuticals Q4 Loss Narrower Than Estimates, Pipeline in Focus
RCKT incurs a narrower-than-expected fourth-quarter 2024 loss. The company provides updates on its pipeline candidates.